Is Lisinopril Bad for the Kidneys?

Lisinopril is not bad for the kidneys in the vast majority of people who take it. In fact, it belongs to a class of drugs whose main selling point beyond blood-pressure control is kidney protection. Decades of clinical research show that lisinopril slows the progression of kidney disease and reduces the amount of protein spilling into the urine, a key marker of kidney damage. But the story has wrinkles: certain medical situations, drug combinations, and stages of kidney disease can turn this generally protective medication into a genuine risk.

How Lisinopril Protects the Kidneys

Lisinopril is an ACE inhibitor, meaning it blocks the enzyme that produces angiotensin II, a hormone that constricts blood vessels. In the kidneys, angiotensin II preferentially tightens the blood vessel leaving the glomerulus (the tiny filtering unit), which raises the pressure inside the filter. Over time, that elevated pressure damages the delicate filtering membrane and drives protein into the urine. By blocking angiotensin II, lisinopril lowers intraglomerular pressure, reduces proteinuria, and slows the scarring process that leads to progressive kidney failure.

This is not just theoretical. In people with type 1 diabetes and established kidney disease, lisinopril at standard doses reduced urinary albumin excretion by roughly 63%, with higher doses pushing that reduction further. Increasing from 20 mg to 40 mg daily produced an additional 23% drop in protein loss beyond what blood-pressure lowering alone would explain.¹ That extra benefit independent of blood pressure is the hallmark of what researchers call “specific renoprotection.”

The protection extends to people without diabetes. A study comparing lisinopril to amlodipine (a calcium channel blocker) in patients with non-diabetic kidney disease found that lisinopril meaningfully reduced proteinuria while amlodipine did not.² A separate trial in patients with mild proteinuria and non-diabetic kidney problems concluded that lisinopril provided renoprotection above and beyond what its blood-pressure effect would predict.³ This is why ACE inhibitors are a first-line recommendation for anyone with chronic kidney disease and proteinuria, regardless of whether diabetes is involved.

The Creatinine Bump That Scares Everyone

If you start lisinopril and your doctor checks blood work a few weeks later, your creatinine level may have risen. Creatinine is a waste product the kidneys filter out, and a higher number usually signals worse kidney function. So it seems alarming. But with ACE inhibitors, a modest rise is expected and actually a sign the drug is working. Because lisinopril lowers the pressure inside the glomerulus, the filtration rate dips slightly at first. That is exactly the mechanism that protects the kidney long-term by easing the strain on the filter.

A review in JAMA Internal Medicine found a strong association between early creatinine increases of up to 30% and better long-term kidney preservation. The authors recommended that doctors should only stop an ACE inhibitor if creatinine climbs more than 30% above baseline within the first two months, or if potassium rises to dangerous levels.⁴ In a large study of patients prescribed lisinopril, only about 0.2% experienced a dramatic creatinine spike from normal levels to above 2.5 mg/dL, and none of those patients developed end-stage kidney disease. The cases that did occur were linked to other factors like heart failure, dehydration, or infection.⁵

The practical message: a small creatinine rise after starting lisinopril does not mean the drug is hurting your kidneys. In most cases, it means the opposite. The threshold that should prompt your doctor to reconsider is a rise beyond 30%, and that kind of jump usually points to an underlying problem rather than to the drug itself.

When Lisinopril Actually Can Hurt the Kidneys

There are a few well-defined situations where lisinopril poses a real kidney risk. These are not subtle edge cases; they are serious enough that they change prescribing decisions.

Renal Artery Stenosis

If one or both arteries supplying blood to the kidneys are severely narrowed, the kidneys depend on angiotensin II to maintain filtration pressure. Block that hormone with lisinopril, and the affected kidney can essentially shut down. A case report described an elderly woman with bilateral renal artery occlusion whose creatinine soared to 11.7 mg/dL after just two days of lisinopril, ultimately requiring dialysis.⁶ Bilateral renal artery stenosis is a recognized contraindication for ACE inhibitors, and even narrowing on one side warrants careful monitoring. This is one reason doctors sometimes check kidney function shortly after starting the drug.

The Triple Whammy

Combining an ACE inhibitor (or a related drug called an ARB) with a diuretic and a nonsteroidal anti-inflammatory drug (NSAID) like ibuprofen creates a convergence of kidney stresses that clinicians call the “triple whammy.” The ACE inhibitor reduces pressure inside the glomerulus, the diuretic lowers overall blood volume, and the NSAID constricts the blood vessel feeding the glomerulus. Together, they can starve the kidney of blood flow and trigger acute kidney injury. A Spanish population study found the hospitalization rate for this type of acute kidney injury was about 9 cases per 1,000 users per year in people taking the triple combination.⁷ About 78% of those hospitalized were over 70 years old. A nationwide Japanese study confirmed that the combination of these three drug classes raises acute kidney injury risk.⁸

This matters because NSAIDs are over-the-counter drugs people take casually. If you are on lisinopril and a diuretic (commonly prescribed together for blood pressure), reaching for ibuprofen during a headache or joint pain is riskier than you might think. Acetaminophen is generally a safer pain reliever in that situation.

Pregnancy

ACE inhibitors are well established as harmful to the developing fetus, particularly in the second and third trimesters. The fetal kidneys are especially vulnerable: lisinopril-induced fetal hypotension leads to prolonged reduction in glomerular filtration, which can cause irreversible kidney damage or death. A review of published cases found that 6 of 14 neonates with renal failure after maternal ACE inhibitor use died.⁹ The perinatal mortality rate associated with ACE inhibitor use in later pregnancy has been reported at about 97 per 1,000.¹⁰ This makes lisinopril absolutely contraindicated during pregnancy, and women of childbearing age on the drug need reliable contraception or an alternative medication if pregnancy is planned.

The Potassium Problem

Lisinopril reduces the body’s production of aldosterone, a hormone that tells the kidneys to excrete potassium. Less aldosterone means potassium stays in the blood. For most people with healthy kidneys, this is a non-issue. But as kidney function declines, the risk of dangerously high potassium (hyperkalemia) climbs. A study that developed a risk prediction model for hyperkalemia in people with chronic kidney disease starting lisinopril found that the risk ranged from about 0.7% in the lowest-risk group to 6.9% in the highest-risk group. Predictors of higher risk included lower kidney function, diabetes, heart failure, use of potassium-sparing diuretics, potassium supplements, and higher lisinopril doses.¹¹ The risk increased gradually as kidney function declined, with no sharp cutoff below which lisinopril was clearly unsafe.

Hyperkalemia is clinically important because it can cause dangerous heart rhythm disturbances. This is why doctors monitor potassium levels after starting or increasing lisinopril, especially in people with existing kidney impairment. It does not mean the drug is damaging the kidneys, but it is a kidney-related complication that requires attention.

Why Doubling Up on Kidney-Protecting Drugs Backfires

Because ACE inhibitors and ARBs both target the same hormone system, a reasonable-sounding idea is to use both together for double the kidney protection. Trials have emphatically shown this does not work. The VA NEPHRON-D trial randomized patients with diabetic kidney disease to lisinopril plus the ARB losartan versus lisinopril alone. The combination failed to improve kidney outcomes and substantially increased adverse events: the rate of acute kidney injury roughly doubled, and hyperkalemia events more than doubled compared to monotherapy.¹² The ONTARGET trial, in a broader high-risk population, reached the same conclusion: combining an ACE inhibitor with an ARB provided no additional benefit and worsened side effects.¹³ Dual blockade of this hormone system is now broadly discouraged in clinical practice.

Dosing in Kidney Disease

Lisinopril has a quirk that sets it apart from some other ACE inhibitors: it is cleared entirely by the kidneys. It is not metabolized by the liver at all. This means that as kidney function declines, lisinopril accumulates in the body. A pharmacokinetic study in patients with severe kidney impairment found that lisinopril’s blood levels increased by about 162% over ten days of dosing, far more than fosinopril (about 27%) or enalapril (about 77%) under the same conditions.¹⁴ Fortunately, adjusting the dose to match kidney function prevents this accumulation and keeps the drug safe.¹⁵

The takeaway here is not that lisinopril should be avoided in kidney disease; it is that the dose needs to be calibrated. Some doctors switch to an ACE inhibitor with a liver-based clearance pathway (like fosinopril) in advanced kidney disease for simpler dosing, but lisinopril remains safe at adjusted doses.

Should You Stop Lisinopril When Kidney Function Gets Very Low?

This is one of the more contentious questions in nephrology. The logic for stopping sounds appealing: if the kidneys are badly damaged, maybe the initial filtration-rate dip caused by ACE inhibitors is no longer worth the tradeoff. Some clinicians have observed that creatinine levels seem to stabilize or improve after stopping. A contrarian review argued that continued ACE inhibitor use in advanced kidney disease may contribute to episodes of acute kidney failure and questioned the assumption of universal renoprotection.

The strongest evidence against stopping came from the STOP-ACEi trial, published in the New England Journal of Medicine. Patients with advanced, progressive chronic kidney disease (filtration rates below 30 mL/min) were randomly assigned to either stop or continue their ACE inhibitor or ARB. After three years, kidney function was essentially the same in both groups, with a slight numerical advantage for those who kept taking the drug.¹⁶ A meta-analysis that pooled data from multiple studies went further, finding that patients who stopped had a roughly 29% higher rate of progressing to end-stage kidney disease and 38% more cardiovascular events compared to those who continued.¹⁷

Current evidence leans toward continuing ACE inhibitors even in advanced kidney disease, with appropriate dose adjustments and monitoring. Stopping does not appear to rescue kidney function, and it may expose patients to more cardiovascular harm.

Lisinopril Around Surgery

Whether to hold lisinopril before a major operation is a practical question many patients face. The concern is that the drug’s blood-pressure-lowering effect, combined with anesthesia, can cause dangerous drops in blood pressure during surgery, which in turn could reduce blood flow to the kidneys. A large prospective study found that withholding ACE inhibitors before major non-cardiac surgery did not actually reduce the risk of post-operative acute kidney injury.¹⁸ A systematic review of randomized trials found that withholding the drugs did reduce intraoperative blood-pressure drops and vasopressor use but did not clearly improve kidney or other clinical outcomes.¹⁹ Practices vary by institution. Many anesthesiologists still recommend holding the drug the morning of surgery, but the kidney-specific rationale for doing so is weaker than commonly assumed.

Heart Failure and the Kidney Connection

A failing heart sends less blood to the kidneys, which triggers the kidneys to activate the very hormone system (the renin-angiotensin system) that lisinopril blocks. In heart failure, angiotensin II levels in kidney tissue can rise dramatically.²⁰ Lisinopril in this setting increases blood flow to the kidneys while modestly lowering the filtration rate, a pattern consistent with its known mechanism of reducing intraglomerular pressure.²¹ The filtration dip can look worrying on lab tests, but the increase in overall renal blood flow is beneficial. Because heart failure itself harms the kidneys, treating the heart with an ACE inhibitor indirectly helps the kidneys by improving cardiac output over time.

Kidney Transplant Recipients

People with transplanted kidneys often develop high blood pressure and proteinuria, both of which threaten the new organ. A systematic review of randomized controlled trials found that ACE inhibitors and ARBs reduced proteinuria by an average of about 470 mg per day in kidney transplant recipients with at least a year of follow-up.²² Proteinuria after transplant is a predictor of graft loss, so reducing it matters. However, transplant recipients are also at higher risk for the creatinine bumps and potassium rises discussed earlier, so monitoring is especially important in this population.

Newer Drug Pairings With Lisinopril

While pairing lisinopril with an ARB proved harmful, combining it with a newer class of drug called SGLT2 inhibitors (originally developed for diabetes) has shown promise. In animal models of diabetic kidney disease, combining lisinopril with dapagliflozin (an SGLT2 inhibitor) stopped the decline in kidney filtration rate and increased the percentage of healthy glomeruli from 14% to 26%, with reduced scarring and tubular damage.²³ A separate rodent study confirmed that the combination provided greater kidney protection than either drug alone.²⁴ These are animal studies, not human trials of this specific pairing, but large human trials of SGLT2 inhibitors added to standard care (which usually includes an ACE inhibitor) have already shown clear kidney benefits in people with chronic kidney disease. The two drugs work through different mechanisms: the ACE inhibitor relaxes the outgoing blood vessel of the glomerulus while the SGLT2 inhibitor constricts the incoming one, and together they restore a more normal pressure inside the filter.

How Lisinopril Compares to Other Blood Pressure Drugs for Kidneys

Not all blood pressure medications protect the kidneys equally. The ALLHAT trial, one of the largest hypertension studies ever conducted, compared lisinopril to amlodipine and a diuretic. Analysis of kidney outcomes showed that amlodipine’s effect on the kidney’s tiny blood vessels can actually increase pressure inside the glomerulus, drive more protein into the urine, and promote scarring, essentially the opposite of what lisinopril does.²⁵ Diuretics lower blood pressure effectively but do not offer the same intraglomerular pressure reduction. For someone whose primary concern is protecting kidney function, ACE inhibitors and ARBs remain the preferred drug classes, and lisinopril is among the most widely prescribed and studied of the bunch.

The comparison matters because patients sometimes hear that lisinopril “affects the kidneys” and assume a calcium channel blocker or diuretic would be gentler. In terms of kidney protection specifically, the evidence consistently favors ACE inhibitors for anyone with proteinuria or established kidney disease.